Glimepirid Stada

Glimepirid Stada is a prescription oral medication that contains the active ingredient glimepiride. It belongs to the sulfonylurea class of antidiabetic drugs and is marketed in the European Union. The product’s specific strength and dosage form are not detailed in the available information, but it is intended for oral administration to help manage blood glucose levels in adults with type 2 diabetes mellitus.

Glimepirid Stada is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It is typically used when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin or other oral antidiabetic agents. - May be prescribed for patients who have not achieved target HbA1c with lifestyle changes alone. - Used as an adjunct to diet and exercise to maintain long‑term glucose control. - Suitable for adult patients with established type 2 diabetes.

Glimepirid Stada may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common: - Hypoglycemia (low blood sugar) - Headache - Dizziness - Nausea or gastrointestinal upset - Weight gain - Skin rash or itching

Serious: - Severe hypoglycemia with loss of consciousness - Allergic reactions such as swelling of the face, lips, or throat - Hepatotoxicity (liver injury) - Hematologic abnormalities like leukopenia or thrombocytopenia

Before starting Glimepirid Stada, patients should consider several safety factors to reduce the risk of complications.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Review history of hypoglycemia or episodes of severe low blood sugar. - Use caution in elderly patients who may be more sensitive to glucose fluctuations. - Monitor blood glucose regularly to adjust dosage as needed. - Discuss pregnancy or breastfeeding plans with a healthcare provider, as safety data are limited. - Avoid abrupt discontinuation without medical guidance to prevent rebound hyperglycemia.

Glimepirid Stada can interact with other medicines, influencing its effectiveness or increasing the risk of adverse effects.

Avoid: - Other sulfonylureas or insulin, which can cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride levels. - MAO‑B inhibitors, which may potentiate hypoglycemic response.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function. - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may alter blood glucose control. - Antidepressants such as SSRIs, which have been reported to affect glycemic regulation.